# Diabetes Research Hub — Monitor Report
**Run date:** 2026-07-04 (automated)
**Previous report:** monitor_report_2026-07-03.md
**Comparison window:** 2026-07-03 → 2026-07-04 snapshots

---

## Bottom line
Quiet data day on the local hub: **zero clinical-trial changes** and a normal PubMed churn (42 in / 50 out) since yesterday. The only items worth your attention are external — the **retatrutide Phase 3 T2D/obesity readout** and **Tzield (teplizumab) Stage 3 T1D approval**, both from the June ADA cycle, plus one **Orforglipron long-term safety results posting (2026-06-30)** now visible in our trial snapshot. No action required beyond optional tracker updates. All five core data files are fresh (regenerated 02:05–02:24 today).

---

## File System Status
All five monitored outputs are present and current (generated today):

| File | Size | Generated |
|------|------|-----------|
| hub_monitor_report.md | 5.8 KB | 2026-07-04 02:24 |
| clinical_trials_latest.json | 566 KB | 2026-07-04 02:05 |
| pubmed_recent_latest.json | 118 KB | 2026-07-04 02:05 |
| literature_gap_data.json | 124 KB | 2026-07-04 02:24 |
| literature_gap_report.md | 4.1 KB | 2026-07-04 02:24 |

Hub file census: 1,007 files tracked; 3 new, 31 modified, 0 removed since the prior scan. The 3 new files are today's dated snapshots and yesterday's monitor report — expected.

**Staleness flag (from hub_monitor.py):** 775 result files older than 14 days. This is mostly the historical snapshot archive (daily since 2026-03-15) and the paper library, so it is expected rather than a problem. `Dashboards/Paper_Library.html` is **0 bytes** — worth a one-line check on whichever script writes it.

---

## Clinical Trial Changes
**Snapshot diff 2026-07-03 → 2026-07-04: 0 new, 0 removed, 0 status changes, 0 new results.** Nothing moved on the local mirror in the last 24h.

Standing totals (839 trials): T1D Cure & Cell Therapy 152 · T1D Immunotherapy & Prevention 74 · T2D Novel Therapies (Ph2-3) 147 · Diabetes Technology 230 · Recently Completed w/ Results 310.

**Key Phase 3 trials from watched sponsors, current status** [Certain — pulled from clinical_trials_latest.json]:

| NCT | Sponsor | Therapy | Status |
|-----|---------|---------|--------|
| NCT06832410 | Vertex | VX-880 (zimislecel) | RECRUITING |
| NCT04786262 | Vertex | VX-880 (zimislecel) | RECRUITING |
| NCT07222332 | Eli Lilly | Baricitinib (beta-cell preservation) | RECRUITING |
| NCT07222137 | Eli Lilly | Baricitinib (delay Stage 3 T1D) | RECRUITING |
| NCT07076199 | Novo Nordisk | Insulin icodec (weekly) | RECRUITING |
| NCT07564414 | Novo Nordisk | CagriSema (dose comparison) | RECRUITING |
| NCT06739122 | Eli Lilly | Dulaglutide (pediatric) | RECRUITING |
| NCT05929079 / NCT06260722 / NCT06297603 | Eli Lilly | Retatrutide | ACTIVE_NOT_RECRUITING |
| NCT06972472 / NCT06993792 / NCT07613307 | Eli Lilly | Orforglipron | ACTIVE / NOT_YET |

**Recently posted results worth a look** [Certain — results_posted field]:
- **NCT06010004** — Orforglipron (LY3502970) long-term safety, Eli Lilly — results posted **2026-06-30** (within the last week). Not yet reflected as a "change" because it entered the mirror already flagged; verify it is captured in the tracker.
- NCT05514535 — Semaglutide combination, Novo — results 2026-05-11.
- NCT05823948 — Once-weekly flash-glucose study, Novo — results 2026-04-30.

48 diabetes trials are Phase 3 + RECRUITING overall.

---

## PubMed Highlights
Snapshot diff 2026-07-03 → 2026-07-04: **42 new papers, 50 dropped** (rolling 30-day window, 152 unique papers across 16 domains). Normal churn.

**Cross-domain new papers (highest value — 8 flagged this run)** [Certain — from hub diff]:
- [42398072] *A historical journey of metabolite-protein interaction discovery: data harmonization to AI-driven…* — **4 domains** (AI/ML, Biomarker, Microbiome, Multi-Omics). Most cross-cutting item this run; aligns with **Tier 1 #1 Multi-Omics Integration**.
- [42394981] *Efficacy and safety of incretin-based therapies in T2D: a network meta-analysis* — T2D GLP-1 + **orforglipron + retatrutide**. Direct hit on two watched therapies.
- [42396665] *Oral–gut axis in systemic disease: barrier-metabolism-immunity model* — Microbiome, Gene Therapy, Multi-Omics.
- [42399485] *Multi-omics integration identifies macrophage senescence (RUNX1-P53 axis)* — AI/ML, Multi-Omics.
- [42394776] Pulmonary embolism Mendelian randomization — T2D Remission, Microbiome, Multi-Omics (likely peripheral relevance; verify before citing).
- [42397093], [42398077], [42399225] — AI/ML + Biomarker / Remission / Microbiome intersections.

**Key-therapy mentions this window** [Certain — therapy_hits]: dapagliflozin 52 · orforglipron 12 · teplizumab 7 · retatrutide 6 · CagriSema 5 · icodec 5 · baricitinib 4 · **zimislecel 0**. Zimislecel remains publication-silent despite active Phase 3 recruitment — a watch item, not a gap.

**Volume trends:** highest-activity domains are AI/ML (210 hits), T2D GLP-1 New (175), Microbiome (171), Biomarker (128). Lowest: **GLP-1 Pharmacogenomics (0)** and Epigenetics (3) — persistently thin, consistent with prior runs.

---

## Gap Analysis Summary
Top 5 under-researched intersections (gap score 100/100, HIGH) [Certain — literature_gap_report.md, 435 pairs, 30 domains]:

1. **Beta Cell Regen × Health Equity** — 0 joint pubs (expected ~1,696)
2. **Insulin Resistance × Islet Transplant** — 1 (expected ~2,216)
3. **Insulin Resistance × Closed Loop / AP** — 3 (expected ~6,125)
4. **Islet Transplant × GWAS / Polygenic** — 0 (expected ~1,144)
5. **Islet Transplant × Personalized Nutrition** — 0 (expected ~402)

**Alignment with our Tier 1 contribution areas:** several top gaps sit squarely in Tier 1 territory and are the most defensible to pursue —
- **Islet Transplant × Drug Repurposing** (rank 6) → Tier 1 #4 Drug Repurposing.
- **Beta Cell Regen × Health Equity** (rank 1) and **Islet Transplant × Health Equity** (rank 8) → Tier 1 #6 Epidemiological / Health Equity.
- **Islet Transplant × GWAS/Polygenic** (rank 4) → Tier 1 #1 Multi-Omics.

Caveat carried from the report itself: low counts can reflect terminology mismatch rather than true whitespace — validate with a manual PubMed query before committing analysis time.

---

## Breaking News (web, last ~2 weeks)
Flagged only genuinely significant items; all trace to the mid-June ADA 2026 Scientific Sessions cycle, so they are recent but not brand-new this week.

- **Retatrutide — first Phase 3 T2D + obesity results** [Likely]. ~2% A1c reduction from 7.9% baseline and up to ~70 lb weight loss on 12 mg, presented at ADA 2026. Directly relevant to our Lilly retatrutide trials (NCT05929079 / NCT06260722 / NCT06297603). ([ADA press release](https://diabetes.org/newsroom/press-releases/breakthrough-studies-demonstrate-effectiveness-first-triple-hormone-therapy))
- **Tzield (teplizumab) — approved for Stage 3 T1D in the U.S., 2026-06-12** [Likely]. Extends teplizumab beyond delay-of-onset; relevant to our T1D Immunotherapy domain and teplizumab tracking (7 mentions this window). ([Type1Strong](https://www.type1strong.org/blog-post/type-1-diabetes-breakthroughs-to-watch-in-2026))
- **Vertex VX-880 / zimislecel — Phase 3, ~83% insulin independence reported** [Guessing on exact figure]. Aligns with our two RECRUITING Vertex Phase 3 trials; regulatory filing anticipated 2026–2027. Confirm the number against a primary source before citing. ([Breakthrough T1D](https://www.breakthrought1d.org/news-and-updates/disease-modifying-therapies-and-diagnode-3-update/))
- Context: **Orforglipron (Foundayo)** received FDA approval **2026-04-01** for weight management (not diabetes); the diabetes ATTAIN-2 program continues. Matches the NCT06010004 results posting noted above. ([Lilly](https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill))

Evidence note per Research Doctrine: web items above are press-release / secondary-source level ([Likely]/[Guessing]), not peer-reviewed endpoints. Do not elevate to tracker "results" status until primary publications or ClinicalTrials.gov results are confirmed.

---

## Recommended Actions
1. **Verify Orforglipron NCT06010004 results (posted 2026-06-30) are captured** in Diabetes_Research_Tracker.xlsx — it is the only new external result touching our watched therapies this week.
2. **Log the retatrutide Phase 3 ADA readout and Tzield Stage 3 approval** as tracker events (evidence level: secondary/press). Pull the primary sources when convenient to upgrade [Likely] → [Certain].
3. **Pick one Tier 1-aligned gap to action** — recommend *Islet Transplant × Drug Repurposing* (Tier 1 #4, computationally tractable, 0 joint pubs). Run a manual PubMed validation query first to rule out terminology mismatch.
4. **One-line fix:** `Dashboards/Paper_Library.html` is 0 bytes — check the writer script on the next dashboard build.
5. **No refresh needed:** all five core datasets regenerated today. Gap analysis is <1 day old. Next scheduled monitor run will re-diff automatically.

*Data unchanged vs. yesterday except normal PubMed rotation; no trial movement. Do NOT treat this as a stale-data run — files are current.*

---
*Generated by the Diabetes Research Hub automated monitor — 2026-07-04. Review run only; no source files were modified.*
